FT
Franklin Templeton Inc disclosed a 5.2% stake in CTNM
Franklin Templeton Inc reported owning 5.2% of Contineum Therapeutics, Inc. (CTNM) (1,704,550 shares) in a Schedule 13G filed Oct 28, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 28, 2026
- Source
- Schedule 13G